Systematic review on epidemiology of Escherichia coli in bloodstream infection of patients undergoing hematopoietic stem cell transplantation.

IF 1.7 Q3 INFECTIOUS DISEASES
GERMS Pub Date : 2024-03-31 eCollection Date: 2024-03-01 DOI:10.18683/germs.2024.1420
Fatemeh Janani, Pouria Azami, Mohammad Ghenaatpisheh Sanani, Khadijeh Bamneshin
{"title":"Systematic review on epidemiology of <i>Escherichia coli</i> in bloodstream infection of patients undergoing hematopoietic stem cell transplantation.","authors":"Fatemeh Janani, Pouria Azami, Mohammad Ghenaatpisheh Sanani, Khadijeh Bamneshin","doi":"10.18683/germs.2024.1420","DOIUrl":null,"url":null,"abstract":"<p><strong>Introduction: </strong>We aimed to conduct a systematic review of the epidemiology of <i>Escherichia coli</i> in bloodstream infections (BSI) of hematopoietic stem cell transplantation patients.</p><p><strong>Methods: </strong>For a comprehensive search of studies that reported the prevalence of <i>E. coli</i> and antibiotic resistance in bloodstream infections from 2000 to January 1, 2024, databases such as PubMed, EMBASE, Google Scholar, Scopus, and Web of Science were searched. The main keywords used were: <i>Escherichia coli</i>, epidemiology, bloodstream infection, microbial resistance, antibiotic resistance, hematopoietic malignancy, hematopoietic stem cell transplantation. After applying eligibility criteria, and quality assessment of studies, data analysis was done by comprehensive meta-analysis (CMA) software.</p><p><strong>Results: </strong>The prevalence of bacterial bloodstream infections amongst different studies varied between 8-51%. Also, bloodstream infections caused by <i>E. coli</i> varied between 2.5-57%. Prevalence of extended-spectrum β-lactamases (ESBLs) of <i>Escherichia coli</i> in bloodstream infections varied between 15-80%. As well, the mortality rate caused by <i>Escherichia coli</i> strains in bloodstream infection varied between 6.7-27.3%. Resistance to ciprofloxacin, cefepime, third- and fourth-generation cephalosporins, was reported to be the highest (prevalence of 100%), and the lowest was against amikacin, with a prevalence between 13-38%.</p><p><strong>Conclusions: </strong>The high prevalence of <i>Escherichia coli</i>-related BSI, and subsequent mortality, especially by multidrug resistance and ESBL strains, in patients undergoing hematopoietic stem cell transplantation, requires essential measures to prevent the spread of microbial resistance.</p>","PeriodicalId":45107,"journal":{"name":"GERMS","volume":null,"pages":null},"PeriodicalIF":1.7000,"publicationDate":"2024-03-31","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11333837/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"GERMS","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.18683/germs.2024.1420","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2024/3/1 0:00:00","PubModel":"eCollection","JCR":"Q3","JCRName":"INFECTIOUS DISEASES","Score":null,"Total":0}
引用次数: 0

Abstract

Introduction: We aimed to conduct a systematic review of the epidemiology of Escherichia coli in bloodstream infections (BSI) of hematopoietic stem cell transplantation patients.

Methods: For a comprehensive search of studies that reported the prevalence of E. coli and antibiotic resistance in bloodstream infections from 2000 to January 1, 2024, databases such as PubMed, EMBASE, Google Scholar, Scopus, and Web of Science were searched. The main keywords used were: Escherichia coli, epidemiology, bloodstream infection, microbial resistance, antibiotic resistance, hematopoietic malignancy, hematopoietic stem cell transplantation. After applying eligibility criteria, and quality assessment of studies, data analysis was done by comprehensive meta-analysis (CMA) software.

Results: The prevalence of bacterial bloodstream infections amongst different studies varied between 8-51%. Also, bloodstream infections caused by E. coli varied between 2.5-57%. Prevalence of extended-spectrum β-lactamases (ESBLs) of Escherichia coli in bloodstream infections varied between 15-80%. As well, the mortality rate caused by Escherichia coli strains in bloodstream infection varied between 6.7-27.3%. Resistance to ciprofloxacin, cefepime, third- and fourth-generation cephalosporins, was reported to be the highest (prevalence of 100%), and the lowest was against amikacin, with a prevalence between 13-38%.

Conclusions: The high prevalence of Escherichia coli-related BSI, and subsequent mortality, especially by multidrug resistance and ESBL strains, in patients undergoing hematopoietic stem cell transplantation, requires essential measures to prevent the spread of microbial resistance.

造血干细胞移植患者血流感染大肠埃希菌流行病学系统综述。
简介:我们旨在对造血干细胞移植患者血流感染(BSI)中大肠埃希菌的流行病学进行系统回顾:我们旨在对造血干细胞移植患者血流感染(BSI)中大肠埃希菌的流行病学进行系统回顾:为了全面检索2000年至2024年1月1日期间报告血流感染中大肠埃希菌流行率和抗生素耐药性的研究,我们检索了PubMed、EMBASE、Google Scholar、Scopus和Web of Science等数据库。使用的主要关键词有大肠杆菌、流行病学、血流感染、微生物耐药性、抗生素耐药性、造血恶性肿瘤、造血干细胞移植。在应用资格标准和对研究进行质量评估后,采用综合荟萃分析(CMA)软件进行了数据分析:结果:不同研究中细菌性血流感染的发病率在8%-51%之间。此外,由大肠杆菌引起的血流感染率在 2.5-57% 之间。血流感染中大肠埃希菌扩谱β-内酰胺酶(ESBLs)的流行率介于 15-80% 之间。此外,大肠埃希菌菌株在血液感染中造成的死亡率介于 6.7% 至 27.3% 之间。据报道,大肠埃希菌对环丙沙星、头孢吡肟、第三代和第四代头孢菌素的耐药性最高(流行率为 100%),对阿米卡星的耐药性最低,流行率在 13% 至 38% 之间:结论:在接受造血干细胞移植的患者中,与大肠埃希菌相关的BSI发病率很高,随后的死亡率也很高,尤其是耐多药和ESBL菌株,因此需要采取必要措施防止微生物耐药性的传播。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
GERMS
GERMS INFECTIOUS DISEASES-
CiteScore
2.80
自引率
5.00%
发文量
36
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信